Streetbeat News

NPCE

NeuroPace, Inc.

https://www.neuropace.com

Industry

Medical - Devices

NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Wells Fargo analyst Lawrence Biegelsen upgraded NeuroPace (NASDAQ:NPCE) from Equal-Weight to Overweight and increased the price target from $16 to $20.

Portfolio Pulse from Benzinga Newsdesk

March 14, 2024 | 1:18 pm

NeuroPace shares surged following JP Morgan's decision to maintain an Overweight rating on the stock, while also increasing its price target from $9 to $17.

Portfolio Pulse from Benzinga Newsdesk

March 14, 2024 | 1:00 pm

NeuroPace (NASDAQ:NPCE) has seen varied analyst ratings over the last quarter, with a shift towards more bullish sentiments in the last 30 days. The average 12-month price target for NPCE has been raised to $16.33, indicating a 48.45% increase from the previous target of $11.00. Analysts from JP Morgan, Cantor Fitzgerald, Morgan Stanley, Wells Fargo, Leerink Partners, and Lake Street have adjusted their ratings and price targets, reflecting changing market dynamics and company performance. NeuroPace, a medical device company focusing on epilepsy treatment, has shown a notable revenue growth rate of 40.84% as of December 31, 2023, but struggles with a high debt-to-equity ratio of 3.51 and below-average ROE and ROA.

Portfolio Pulse from Benzinga Insights

March 12, 2024 | 2:00 pm

JP Morgan analyst Robbie Marcus has maintained an Overweight rating on NeuroPace (NASDAQ:NPCE) and increased the price target from $9 to $17.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 1:07 pm

Cantor Fitzgerald analyst Ross Osborn maintains an Overweight rating on NeuroPace (NASDAQ:NPCE) and raises the price target from $16 to $18.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 5:28 pm

Morgan Stanley analyst Drew Ranieri maintains an Equal-Weight rating on NeuroPace (NASDAQ:NPCE) and raises the price target from $9 to $13.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 5:15 pm

NeuroPace has projected its full-year 2024 revenue to be between $73M and $77M, closely aligning with the estimated $74.598M. The company anticipates a gross margin of 72% to 74% and total operating expenses between $80M and $84M, which includes around $12M in stock-based compensation.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 10:28 pm

NeuroPace (NASDAQ:NPCE) reported Q4 earnings with an EPS of $-0.23, beating estimates by 26.0% and showing a revenue increase of $5.22 million from the previous year. Despite past earnings beats, such as last quarter's $0.13 EPS beat, the share price dropped 2.0% the following day. The company has consistently outperformed EPS estimates over the past four quarters.

Portfolio Pulse from Benzinga Insights

March 05, 2024 | 9:35 pm

NeuroPace (NASDAQ:NPCE) reported Q4 2023 earnings with a GAAP EPS of $(0.23), surpassing the $(0.32) estimate, and sales of $18.01M, exceeding the $17.46M estimate. This represents a 40.84% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 9:33 pm

Earnings reports for March 5, 2024, include a mix of expected quarterly losses and earnings from various sectors. Notable companies like NIO, Target, and Nordstrom are among those reporting. The reports span across different industries, including automotive, retail, biotech, and technology, indicating a broad market impact.

Portfolio Pulse from Benzinga Insights

March 05, 2024 | 10:00 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.